News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Doug Mager, BS

Articles by Doug Mager, BS

Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

ByRobert Valuck, PhD, RPH. Author Reply by Emily R. Cox, PhD,Brenda Motheral, PhD,Doug Mager, BS

April 1st 2004

Verification of a Decision Analytic Model Assumption Using Real-World Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

ByEmily R. Cox, PhD,Brenda Motheral, PhD,Doug Mager, BS

December 1st 2003

Prescribing COX-2s for Patients New to Cyclo-oxygenase Inhibition Therapy

ByEmily R. Cox, PhD,Brenda Motheral, PhD,Mark Frisse, MD*,Andrew Behm, PharmD,Doug Mager, BS

November 1st 2003

Latest Updated Articles

Prescribing COX-2s for Patients New to Cyclo-oxygenase Inhibition Therapy
Published: November 1st 2003 | Updated:
Verification of a Decision Analytic Model Assumption Using Real-World Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)
Published: December 1st 2003 | Updated:
Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)
Published: April 1st 2004 | Updated:

Trending on AJMC

Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

New Biomarkers, Drug Targets Identified for Colorectal Cancer

Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations

First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.